The Woodlands, Texas (PRWEB) October 12, 2012
VGXI, Inc., a leading provider of DNA plasmid manufacturing and development services, announced today that it has successfully scaled-up and completed two large-scale cGMP fermentation runs using Nature Technology Corporation’s (NTC) HyperGRO™ fermentation system, including their antibiotic-free selection vector. VGXI has been able to achieve reproducible plasmid yields of up to 1.8 g/L at the 320L scale, the largest fermentation scale yet using the HyperGRO™ technology.
VGXI entered into a manufacturing agreement with Coridon Pty Ltd earlier this year to manufacture Coridon’s Herpes Simplex Virus 2 DNA vaccine for their upcoming Phase I clinical trial. Coridon requested VGXI use HyperGRO™ fermentation technology to satisfy their project’s unique requirements.
The data will be presented on a collaborative poster at the DNA Vaccines Conference to be held December 5-7, 2012 in San Diego, CA.
About VGXI, Inc.
VGXI Inc. is a leading provider of DNA plasmid manufacturing and development services for DNA vaccine and gene therapy research. The Company has an outstanding track record of success in manufacturing plasmid products under GMP conditions for client clinical studies in the US and Europe, and its GMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI's ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible GMP production facility, and experienced development team. The recently announced research and pre-clinical production services extend the range of high-quality, research grade materials utilizing the same efficient service. This rapid turnaround program provides consistent materials to build a reliable pre-clinical dataset. For information, visit http://www.vgxii.com
About Nature Technology
Nature Technology Corporation is a biotechnology company that provides industry partners with world class technology platforms, including safe and efficacious non-viral vectors (plasmids) and processes for gene therapy and DNA vaccination vector production. NTC also provides cost effective outsourcing of product development services including synthetic gene design, vector construction, plasmid DNA manufacturing and recombinant proteins. For information, visit http://www.natx.com
About Coridon Pty Ltd
Coridon was founded in 2000 by the founder inventor Prof Ian Frazer as a private unlisted company, to develop and commercialize patented technology for improving immune responses to DNA vaccines licensed by UniQuest Pty Ltd and developed at the University of Queensland. The company has laboratories within the research facility at the Princess Alexandra Hospital in Brisbane, working in collaboration with the University of Queensland's Diamantina Institute. Publicly listed Allied Healthcare Group Limited (ASX:AHZ) is a major investor in Coridon. The Company's objective is to utilize its unique optimization technology to produce prophylactic and/or therapeutic DNA vaccines for a range of infectious diseases and cancers in humans. Product development is currently focused on herpes virus vaccines.
Cautionary Factors That May Affect Future Results - Materials in this Web site contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements do not relate strictly to historical or current facts and can therefore be identified as such. They include words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.